DaVita (NYSE:DVA) Rating Lowered to Hold at Zacks Research

DaVita (NYSE:DVA) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

A number of other brokerages also recently issued reports on DVA. Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and lifted their price target for the company from $126.00 to $220.00 in a report on Wednesday, May 6th. Barclays raised their price objective on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Truist Financial boosted their target price on DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research report on Friday, May 8th. TD Cowen raised their price target on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a report on Monday, May 11th. Finally, UBS Group upped their price objective on DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $199.17.

DaVita Price Performance

DVA stock opened at $234.21 on Monday. DaVita has a 1-year low of $101.00 and a 1-year high of $239.64. The business has a 50 day simple moving average of $199.69 and a two-hundred day simple moving average of $158.21. The company has a market capitalization of $15.04 billion, a price-to-earnings ratio of 21.73, a PEG ratio of 0.77 and a beta of 0.88.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same quarter last year, the business posted $2.00 earnings per share. The company’s revenue for the quarter was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Sell-side analysts anticipate that DaVita will post 15.07 EPS for the current fiscal year.

Insider Activity

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the sale, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership increased its position in DaVita by 114.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after acquiring an additional 636,191 shares during the last quarter. Norges Bank purchased a new position in shares of DaVita during the 4th quarter worth about $49,164,000. Corient Private Wealth LLC grew its holdings in DaVita by 1,493.1% during the 4th quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock valued at $40,706,000 after purchasing an additional 335,809 shares during the last quarter. Man Group plc raised its position in DaVita by 1,608.6% in the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after purchasing an additional 269,081 shares during the period. Finally, Voloridge Investment Management LLC raised its position in DaVita by 2,905.7% in the 3rd quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company’s stock worth $30,324,000 after purchasing an additional 220,628 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.